Adamantyl carboxamides and acetamides as potent human 11β- hydroxysteroid dehydrogenase type 1 inhibitors

Xiangdong Su, Heather A. Halem, Mark P. Thomas, Cecille Moutrille, Michael D. Culler, Nigel Vicker, Barry V. L. Potter

Research output: Contribution to journalArticlepeer-review

7 Citations (SciVal)

Abstract

The modulation of 11β-HSD1 activity with selective inhibitors has beneficial effects on various metabolic disorders including insulin resistance, dyslipidemia and obesity. Here we report the discovery of a series of novel adamantyl carboxamide and acetamide derivatives as selective inhibitors of human 11β-HSD1 in HEK-293 cells transfected with the HSD11B1 gene. Optimization based on an initially identified 11β-HSD1 inhibitor (3) led to the discovery of potent inhibitors with IC 50 values in the 100 nM range. These compounds are also highly selective 11β-HSD1 inhibitors with no activity against 11β-HSD2 and 17β-HSD1. Compound 15 (IC 50 = 114 nM) with weak inhibitory activity against the key human cytochrome P450 enzymes and moderate stability in incubation with human liver microsomes is worthy of further development. Importantly, compound 41 (IC 50 = 280 nM) provides a new lead that incorporates an adamantyl group surrogate and should enable further series diversification.
Original languageEnglish
Pages (from-to)6394-6402
JournalBioorganic and Medicinal Chemistry
Volume20
Issue number21
DOIs
Publication statusPublished - 1 Nov 2012

Fingerprint

Dive into the research topics of 'Adamantyl carboxamides and acetamides as potent human 11β- hydroxysteroid dehydrogenase type 1 inhibitors'. Together they form a unique fingerprint.

Cite this